I am a
Home I AM A Search Login

Papers of the Week

Papers: 16 Jul 2022 - 22 Jul 2022

Pharmacology/Drug Development

2022 Jul 09

Biochem Biophys Res Commun


SR 57227A, a serotonin type-3 receptor agonist, as a candidate analgesic agent targeting nociplastic pain.


Nakamura Y, Sumi T, Mitani O, Okamoto T, Kubo E, Masui K, Kondo M, Koyama Y, Usui N, Shimada S
Biochem Biophys Res Commun. 2022 Jul 09; 622:143-148.
PMID: 35863088.


Pain is influenced by various factors, such as fear, anxiety, and memory. We previously reported that pain-like behaviors in mice can be induced by environmental cues in which a pain stimulus was previously presented, and that pain was reduced using fentanyl (an opioid). Although opioid analgesics are currently used to treat persistent pain, their inappropriate use causes a significant number of deaths in the United States. Thus, alternative medicines to opioids are needed. Here, we reported that SR 57227A, a serotonin type-3 receptor agonist, significantly reduced pain-like behaviors. The number of c-Fos positive cells increased by environmental cues in PFC was decreased by SR 57227A. Moreover, SR 57227A reduced pain-like behaviors of the formalin test, and restored reductions in paw withdrawal thresholds by acidic saline intramuscular injection and sciatic nerve ligation. Unlike opioids, SR 57227A induced no preference behaviors as measured by the conditioned place preference test. These data suggested that SR 57227A is an effective alternative pain reliever to opioids that targets chronic pain.